Literature DB >> 18057011

Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.

Yoshitaka Inaba1, Hidekazu Yamaura, Yozo Sato, Mina Najima, Hiroshi Shimamoto, Hideyuki Nishiofuku, Takashi Ura, Kei Muro.   

Abstract

BACKGROUND: The current standard chemotherapy for advanced or metastatic colorectal cancer in Japan is FOLFOX or FOLFIRI therapy. Although both therapies include continuous infusion of 5-fluorouracil (5-FU), outpatient home chemotherapy is possible by placing a central venous access port (CV-port) and using a portable disposable pump. The port system has been placed more frequently since the approval of FOLFOX. Consequently, more complications involving ports and pumps have been encountered.
METHODS: At our hospital, 232 patients with colorectal cancer underwent outpatient home chemotherapy by placing a CV-port and using a portable disposable pump for continuous infusion of 5-FU between 1998 and 2005. Incidence and contents of complications involving ports and pumps were investigated retrospectively.
RESULTS: A total of 54 incidents of complications involving ports and pumps were identified in 3142 treatments (1.72%) from among 34 of the 232 patients (14.7%). In 2005, when FOLFOX was introduced, 31 incidents occurred in 1903 treatments (1.63%) for 19 of 149 patients (12.8%). Incidents involved port placement (n = 6), catheter and port system-related complications (n = 15), puncture needle-related complications (n = 3), skin complications related to tape fixation (n = 20) and pump-related complications (n = 10). In 10 patients (4.3%), system-related complications made therapy difficult to continue and system exchange was required.
CONCLUSIONS: Technical troubles involving ports and pumps occurred at a certain rate, and skin incision was required for system exchange in some cases. When performing outpatient chemotherapy using ports and pumps, thorough prior guidance and double-checking must be implemented, and proper countermeasures must be established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057011     DOI: 10.1093/jjco/hym118

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study.

Authors:  Hitoshi Ohno; Chisaki Mizumoto; Yoshihiro Otsuki; Shigeru Oguma; Yataro Yoshida
Journal:  Int J Clin Oncol       Date:  2010-03-02       Impact factor: 3.402

2.  Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer.

Authors:  Eun-Hye Joo; Sun-Young Rha; Joong Bae Ahn; Hye-Young Kang
Journal:  Support Care Cancer       Date:  2010-05-23       Impact factor: 3.603

3.  Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.

Authors:  Yoichiro Yoshida; Seiichiro Hoshino; Naoya Aisu; Masayasu Naito; Syu Tanimura; Ai Mogi; Toshihiro Tanaka; Keiji Hirata; Kazuo Tamura; Yuichi Yamashita
Journal:  Int J Clin Oncol       Date:  2014-05-10       Impact factor: 3.402

4.  Central venous port-related infection in patients with malignant tumors: an observational study.

Authors:  Akio Akahane; Miyuki Sone; Shigeru Ehara; Kenichi Kato; Michiko Suzuki; Ryoichi Tanaka; Akira Suwabe; Tetsuya Itabashi; Kashiwaba Masahiro
Journal:  Ups J Med Sci       Date:  2012-02-29       Impact factor: 2.384

5.  Effectiveness of a flow confirmation study of a central venous port of the upper arm versus the chest wall in patients with suspected system-related mechanical complications.

Authors:  Hiroyuki Tokue; Azusa Tokue; Yoshito Tsushima
Journal:  World J Surg Oncol       Date:  2022-03-22       Impact factor: 2.754

6.  Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.

Authors:  E Chu; D Haller; T Cartwright; C Twelves; J Cassidy; W Sun; M W Saif; E McKenna; S Lee; H-J Schmoll
Journal:  Br J Cancer       Date:  2014-02-18       Impact factor: 7.640

7.  Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.

Authors:  Rohit Lal; Nawel Bourayou; Gunnar Hillerdal; Marianne Nicolson; Anders Vikstrom; Maria Lorenzo; Yulia D'yachkova; Susana Barriga; Carla Visseren-Grul
Journal:  Health Qual Life Outcomes       Date:  2013-10-03       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.